Dual MAPK pathway inhibition (dabrafenib and trametinib) was proven to have strong anti-tumor activity and good safety profile in patients with BRAF-mutant melanoma brain metastases [116], BRAF-mutant NSCLC [117], and KRAS-mutant-positive NSCLC [118]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.